Leonid Timashev (RBC Capital) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Leonid Timashev's stock ratings?

About 60% of Leonid's ratings were profitable over a one-year hold, with an average return of +4.4% per rating, measured by 13Foresight from historical prices.

Q: How is Leonid ranked?

Leonid Timashev is ranked #495 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Leonid Timashev

RBC

Leonid Timashev

RBC Capital

Wall Street Analyst

★★★★☆

#495

on 13Foresight · ranked by our own returns

60%

Success Rate

+4.3%

Average Return

32 of 53 calls profitable · +3.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 60% of Leonid Timashev's ratings turned a profit when each position was held for 1 year — averaging +4.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

236 Buy 35 Hold 0 Sell

Leonid's Stock Coverage 26 ratings · 2026-07-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
PRAX Praxis Precision Medicines	Jul 10, 2026	BUY	Strong Buy +63.1% avg upside 24 analysts	$449.00 38.22% Upside	+0.0%
EXEL Exelixis	Jul 07, 2026	HOLD	Buy -25.7% avg upside 33 analysts	$46.00 18.54% Downside	-0.7%
JAZZ Jazz Pharmaceuticals	Jul 07, 2026	BUY	Strong Buy -9.6% avg upside 35 analysts	$258.00 5.77% Upside	-0.4%
VSTM Verastem	Jul 07, 2026	BUY	Strong Buy +171.9% avg upside 24 analysts	$14.00 153.21% Upside	+4.7%
AXSM Axsome Therapeutics	Jul 07, 2026	BUY	Strong Buy -5.1% avg upside 28 analysts	$304.00 30.09% Upside	-6.4%
ONC BeOne Medicines	Jul 07, 2026	BUY	Strong Buy +17.3% avg upside 28 analysts	$451.00 51.06% Upside	-3.3%
IDYA IDEAYA Biosciences	Jul 07, 2026	BUY	Strong Buy +32.0% avg upside 29 analysts	$48.00 29.82% Upside	+0.0%
ADCT ADC Therapeutics	Jul 07, 2026	HOLD	Buy +365.1% avg upside 12 analysts	$2.00 55.02% Upside	-3.7%
LEGN Legend Biotech	Jul 07, 2026	BUY	Strong Buy +147.3% avg upside 27 analysts	$63.00 132.59% Upside	+0.0%
CMPS COMPASS Pathways	Jul 07, 2026	BUY	Strong Buy +62.4% avg upside 19 analysts	$22.00 61.22% Upside	+6.5%
NUVB Nuvation Bio	Jul 07, 2026	BUY	Strong Buy +120.6% avg upside 15 analysts	$19.00 226.94% Upside	+3.5%
PYXS Pyxis Oncology	Jul 07, 2026	BUY	Strong Buy +158.8% avg upside 13 analysts	$5.00 87.34% Upside	-12.4%
ALKS Alkermes	Jul 07, 2026	BUY	Strong Buy -25.0% avg upside 34 analysts	$56.00 7.77% Upside	-1.6%
CRMD Cormedix	Jul 07, 2026	BUY	Strong Buy +78.0% avg upside 13 analysts	$13.00 54.77% Upside	-0.4%
CYTK Cytokinetics	Jul 07, 2026	BUY	Strong Buy +3.4% avg upside 36 analysts	$117.00 37.93% Upside	-0.8%
INSM Insmed	Jul 07, 2026	BUY	Strong Buy +50.3% avg upside 36 analysts	$195.00 68.60% Upside	+2.5%
NAMS NewAmsterdam Pharma Company	Jun 30, 2026	BUY	Strong Buy +33.1% avg upside 18 analysts	$51.00 44.61% Upside	+5.9%
CGON CG Oncology, Inc.	Jun 30, 2026	BUY	Strong Buy +14.1% avg upside 17 analysts	$81.00 7.76% Upside	+5.9%
RVMD Revolution Medicines	Jun 26, 2026	BUY	Strong Buy -18.5% avg upside 32 analysts	$182.00 2.62% Downside	+2.6%
BHVN Biohaven Ltd.	Jun 25, 2026	BUY	Buy +47.2% avg upside 25 analysts	$22.00 41.41% Upside	+1.4%
EWTX Edgewise Therapeutics	Jun 17, 2026	BUY	Strong Buy +1.1% avg upside 14 analysts	$59.00 29.96% Upside	+28.2%
DSGN Design Therapeutics	May 18, 2026	BUY	Strong Buy +21.2% avg upside 9 analysts	$20.00 31.72% Upside	+6.6%
JSPR Jasper Therapeutics	May 14, 2026	HOLD	Buy +5271.0% avg upside 17 analysts	$3.00 417.78% Upside	-49.7%
CATX Perspective Therapeutics	May 11, 2026	BUY	Strong Buy +272.8% avg upside 22 analysts	$14.00 365.08% Upside	-22.4%
XNCR Xencor	May 05, 2026	BUY	Strong Buy +106.7% avg upside 27 analysts	$19.00 19.85% Upside	-12.3%
BCYC Bicycle Therapeutics	Apr 30, 2026	HOLD	Strong Buy +449.3% avg upside 20 analysts	$5.00 13.29% Upside	-10.5%

🔒 21 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Leonid Timashev — Frequently Asked Questions

How accurate are Leonid Timashev's stock ratings?

Based on the calls 13Foresight could measure, about 60% of Leonid's ratings were profitable over a one-year hold, with an average return of +4.4% per rating, or +3.2% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Leonid ranked on 13Foresight?

Leonid Timashev is currently ranked #495 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Leonid cover?

Leonid most recently has ratings on PRAX, EXEL, JAZZ, VSTM, AXSM, ONC, IDYA, ADCT, LEGN, CMPS, NUVB, PYXS and 14 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!